Replies to post #2418 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Would they price it purely on revenue maximization vs the clear indications, or cheaper to try to expand its scope of application?<

The latter, according to GTC’s own guidance.

The big underserved market is prophylactic use by hemophiliacs, where obtaining reimbursement would necessitate a substantially lower price than what NovoSeven sells for.

>Care to conjecture what they might ask for it?<

I'll get back to you on that one :-)